A daily tablet that offers up to a 90 per cent reduction in the risk of contracting HIV could soon be available on the NHS, in what is being described as the most significant breakthrough in the battle against the virus in a generation.
A landmark trial in England is to be dramatically sped up after it was found that taking a single dose of the pre-exposure prophylaxis (PrEP) Truvada provided unprecedented levels of protection for those most at risk of infection.